SCM
Soleus Capital Management Portfolio holdings
AUM
$1.45B
This Quarter Return
+16.97%
1 Year Return
+18.23%
3 Year Return
+274.85%
5 Year Return
+440.77%
10 Year Return
–
AUM
$1.2B
AUM Growth
+$1.2B
(+6%)
Cap. Flow
-$60.2M
Cap. Flow
% of AUM
-5%
Top 10 Holdings %
Top 10 Hldgs %
37.95%
Holding
109
New
16
Increased
24
Reduced
36
Closed
22
Top Buys
| 1 |
Grifois
GRFS
|
$40.2M |
| 2 |
Sanofi
SNY
|
$31.7M |
| 3 |
QuidelOrtho
QDEL
|
$31.3M |
| 4 |
Eli Lilly
LLY
|
$17.1M |
| 5 |
Krystal Biotech
KRYS
|
$16.6M |
Top Sells
| 1 |
TG Therapeutics
TGTX
|
$26M |
| 2 |
Nurix Therapeutics
NRIX
|
$22.2M |
| 3 |
Penumbra
PEN
|
$22.2M |
| 4 |
Vaxcyte
PCVX
|
$18.1M |
| 5 |
Humana
HUM
|
$16.6M |
Sector Composition
| 1 | Healthcare | 100% |
| 2 | Consumer Staples | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
AVDL
101
Avadel Pharmaceuticals
AVDL
$1.43B
| – | – |
-509,000
| Closed | -$7.16M |
|
102
CVRx
CVRX
$205M
| – | – |
-587,098
| Closed | -$7.04M |
|
103
Exact Sciences
EXAS
$8.98B
| – | – |
-91,611
| Closed | -$3.87M |
|
104
Fate Therapeutics
FATE
$120M
| – | – |
-870,000
| Closed | -$2.85M |
|
105
4D Molecular Therapeutics
FDMT
$288M
| – | – |
-108,598
| Closed | -$2.28M |
|
106
Globus Medical
GMED
$8.27B
| – | – |
-86,000
| Closed | -$5.89M |
|
107
Hims & Hers Health
HIMS
$9.57B
| – | – |
-333,000
| Closed | -$6.72M |
|
|
108
Humana
HUM
$36.5B
| – | – |
-44,356
| Closed | -$16.6M |
|
109
Inhibrx
INBX
$408M
| – | – |
-88,470
| Closed | -$1.25M |
|